这份公告包含内幕消息
2020年7月27日07:00英国夏令时
潜在的新药DS-1062可能重新定义治疗
肺癌，乳腺癌和其他多种癌症的标准
AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company, (Daiichi Sankyo)为DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for the treatment of multiple tumour types.
DS-1062 is currently in development for the treatment of multiple tumours that commonly express the cell-surface glycoprotein TROP2. 其中，TROP2在大多数非小细胞肺癌中过表达1 还有乳腺癌，2,3 长期以来一直是澳门在线赌城娱乐战略重点的肿瘤类型. This collaboration reflects AstraZeneca’s strategy to invest in antibody drug conjugates as a class, the innovative nature of the technology and the successful existing collaboration with Daiichi Sankyo.
Pascal Soriot, 首席执行官, said: “We see significant potential in this antibody drug conjugate in lung as well as in breast and other cancers that commonly express TROP2. We are delighted to enter this new collaboration with Daiichi Sankyo and to build on the successful launch of Enhertu 进一步扩大澳门第一赌城在线娱乐在肿瘤学领域的产品线和领导地位. We now have six potential blockbusters in Oncology with more to come in our early and late pipelines.”
Sunao Manabe, 代表董事, Daiichi Sankyo的总裁兼首席执行官, said: “DS-1062, 澳门第一赌城在线娱乐的主要DXd adc之一，将成为澳门第一赌城在线娱乐下一个中期业务计划的支柱, 是否有潜力成为治疗多种肿瘤的同类最佳TROP2 ADC, 包括肺癌和乳腺癌. 这次与澳门在线赌城娱乐的新战略合作, a company with extensive experience and significant expertise in the global oncology business, 能让澳门第一赌城在线娱乐尽快将DS-1062交付给全球更多的患者吗. 正如澳门第一赌城在线娱乐所做的那样 Enhertu，澳门第一赌城在线娱乐将共同设计和实施战略，使DS-1062的价值最大化.”
采用Daiichi Sankyo专有的DXd ADC技术, DS-1062 is designed to deliver chemotherapy selectively to cancer cells and to reduce systemic exposure. DS-1062的综合开发计划正在全球范围内进行规划.
金融方面的考虑
AstraZeneca will pay Daiichi Sankyo an upfront payment of $1bn in staged payments: $350m is due upon completion, with $325m after 12 months and $325m after 24 months from the effective date of the agreement.
AstraZeneca will pay additional conditional amounts of up to $1bn for the successful achievement of regulatory approvals and up to $4bn for sales-related milestones.
该交易将作为无形资产收购记帐, 按非或有对价现值初始确认, with any potential future milestone payments capitalised into the intangible asset as they are recognised.
两家公司将共同开发DS-1062并在全球范围内商业化, 除了在日本，第一三共将保持专有权. AstraZeneca and Daiichi Sankyo will share equally development and commercialisation expenses as well as profits relating to DS-1062 worldwide, except for Japan where Daiichi Sankyo will be responsible for such costs and will pay AstraZeneca mid single-digit royalties. 第一三共将在美国创下销量纪录, certain countries in Europe and certain other countries where Daiichi Sankyo has affiliates. Profits shared with AstraZeneca from those countries will be recorded as Collaboration Revenue by AstraZeneca. 澳门在线赌城娱乐将在全球其他国家记录产品销售, 与Daiichi Sankyo分享的利润将记录在销售成本内. 第一三共将生产和供应DS-1062.
交易没有结束条件. 该合作协议于2020年7月27日生效. 该交易不会影响公司2020年的财务指引.
TROP2
TROP2 is a transmembrane glycoprotein that is overexpressed in many cancers including up to 80% of patients with triple-negative breast cancer.2,3 High TROP2 expression also has been identified in a majority of non-small cell lung cancers.1 Research indicates that high TROP2 expression is associated with cancer cell growth and proliferation.4 TROP2 is recognised as a promising molecular target for therapeutic development in various cancers.4
DS-1062
DS-1062是一个trop2定向ADC. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (‘payload’) via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. 采用Daiichi Sankyo专有的DXd ADC技术设计, DS-1062 is comprised of a humanised anti-TROP2 monoclonal antibody attached to a topoisomerase I inhibitor payload by a tetrapeptide-based linker. DS-1062 is a potential new medicine that has not been approved for any indication in any country. 安全性和有效性尚未确定.
澳门在线赌城娱乐与Daiichi Sankyo在肿瘤领域的合作
In March 2019, AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu (HER2-directed ADC) worldwide, except in Japan, where Daiichi Sankyo maintains exclusive rights.
澳门在线赌城娱乐在肿瘤学
AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. 2014年至2020年期间有6种新药上市，并且有广泛的研发渠道 开发中的小分子和生物制剂, the Company is committed to advance oncology as a key growth driver for AstraZeneca focused on lung, ovarian, 乳腺癌和血癌.
通过利用四个科学平台的力量——免疫肿瘤学, 肿瘤驱动因素和耐药性, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalised combinations, 澳门在线赌城娱乐的愿景是重新定义癌症治疗, one day, 消除癌症作为死亡原因.
AstraZeneca
澳门在线赌城娱乐(LSE/STO/NYSE: AZN)是一家全球性制药公司, 以科学为主导的澳门第一赌城在线娱乐公司，专注于发现, 处方药的开发和商业化, 主要用于治疗肿瘤等三个治疗领域的疾病, Cardiovascular, Renal & 新陈代谢和呼吸 & Immunology. 总部设在剑桥, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit 178758.com 并在Twitter上关注公司 @AstraZeneca.
Contacts
References
1. Inamura K, et al. 肿瘤TROP2表达与预后的关系因肺癌亚型而异. Oncotarget. 2017; 8 (17): 28725-28735. http://dx.doi.org/10.18632%2Foncotarget.15647.
2. Zhao W, et al. Trop2是促进人类乳腺癌EMT的潜在生物标志物. Oncol Rep. 2018; 40 (2): 759-766. http://doi.org/10.3892/or.2018.6496.
3. Zaman S, et al. 靶向Trop-2在实体肿瘤中的应用前景. Onco Targets Ther. 2019; 12: 1781-1790. http://dx.doi.org/10.2147%2FOTT.S162447.
4. Zeng P, et al. Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis. Sci Rep. 2016; 6: e33658. http://dx.doi.org/10.1038%2Fsrep33658.
Adrian Kemp
Company Secretary
AstraZeneca PLC